You are here: Industry Insights > Tesaro

News List

GlaxoSmithKline to buy Tesaro for $5.1 billion, gaining PARP inhibitor Zejula firstwordpharma
December 03, 2018
GlaxoSmithKline announced Monday an agreement to acquire Tesaro for around $5.1 billion in cash, gaining the latter's oral PARP inhibitor Zejula (niraparib). GlaxoSmithKline CEO Emma Walmsley said the deal "will strengthen our pharmaceuticals business by
TESARO, Roche to evaluate triplet therapy for ovarian cancer biospectrumasia
June 07, 2018
TESARO and Genentech are also working together to evaluate the combination of ZEJULA and atezolizumab in patients with metastatic bladder cancer as a part of MORPHEUS, Roche's novel cancer immunotherapy development platform.
Tesaro secures EU approval in specific ovarian cancer population pharmafile
November 24, 2017
The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged.
China’s Zai Lab files for $115M Nasdaq IPO to take Tesaro, Bristol-Myers cancer drugs through late-p fiercebiotech
August 17, 2017
A slice of the Zai Lab IPO haul is earmarked for trials of Tesaro's niraparib.
STA signs 5-year Supply Agreement with TESARO pharmaasia
August 08, 2017
STA has signed a 5-year Supply Agreement with TESARO.
STA Signs 5-year supply agreement with TESARO biospectrumasia
July 27, 2017
Under the five-year agreement, STA will provide supplies of certain starting and intermediate materials for the recently launched ZEJULA
STA signs 5-year supply agreement with TESARO cphi-online
July 26, 2017
STA will provide supplies of certain starting and intermediate materials for the recently launched Zejula.
STA Signs Supply Agreement with TESARO en-cphi.cn
July 24, 2017
STA Pharmaceutical Co., Ltd. (STA) announces it signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. (TESARO) for certain starting and intermediate materials for ZEJULA™ (niraparib).
Sanofi, Gilead eyeing the takeover of Tesaro biospectrumasia
June 14, 2017
The company that acquires Tesaro will get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer
Tesaro announces FDA approval of Zejula for women with recurrent ovarian cancer cphi-online
March 31, 2017
Tesaro has announced that the FDA has approved Zejula (niraparib) for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response (CR or PR) to platinumbased

Previous page 1 2 3 Next page